Cumulative incidence of all second cancers (SC), myelodysplasia/acute myeloid leukemia (MDS/AML) and solid tumors (ST) after ASCT in 467 HD patients (PSD, PRD, R1, and R2 groups) with a median follow up of 21 months since ASCT.